Webcasts and presentations from Immuno-Oncology 2015 are now online and can be accessed by ESMO members and event attendees
There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society
ESMO’s flagship scientific journal, Annals of Oncology, publishes editorials, reviews, original articles and letters related to oncology
ESMO's new open access, online journal, ESMO Open is open for submission. Learn more about this exciting launch!
Two drugs are changing the current landscape for the treatment of advanced metastatic renal cell carcinoma, prolonging survival. These two drugs are likely to change the clinical practice, according to Cora Sternberg Chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy. Read more...
01 Dec 2015
Consultation now open on plans to reform Cancer Drugs Fund
30 Nov 2015
First and only PD-1 immune checkpoint inhibitor approved as a single agent for first-line use in advanced BRAF wild-type melanoma
27 Nov 2015
Necitumumab is a monoclonal antibody that blocks activity of EGFR
26 Nov 2015
These medicinal products are intended for unresectable malignant pleural mesothelioma and locally advanced or metastatic NSCLC other than predominantly...
26 Nov 2015
Registration is open for Sarcoma & GIST 2016. Early registration deadline: 13 Jan 2016
25 Nov 2015
It is approved in combination with lenalidomide and dexamethasone